Salix and its lead drug Xifaxan have Valeant sniffing around a deal

Will a buyer scoop up Salix ($SLXP) and its gastrointestinal portfolio soon? Valeant Pharmaceuticals ($VRX) is reportedly eyeing a bid for the troubled drugmaker, which last year confessed to an inventory snafu that overstated its sales. The cash-rich Shire ($SHPG) is also on the hunt. Sterne Agee analyts figure a buyer with GI drugs of its own--like Shire--could afford a bid at least 20% higher than Salix's standalone value of $145. Report

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.